BIOPOR — BioPorto A/S Share Price
Last trade - 00:00- DKK659.25m
- DKK636.65m
- DKK36.24m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 15.91 | ||
| Price to Tang. Book | 16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 19.14 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -189.56% | ||
| Return on Equity | -197.6% | ||
| Operating Margin | -265.73% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | DKKm | 23.2 | 24.25 | 28.97 | 30.96 | 36.24 | 52.25 | n/a | 6.36% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Directors
- Thomas Magnussen CHM (63)
- Anthony Pare CEO (59)
- Torben Nielsen VCH (56)
- Neil Goldman CFO (53)
- Jan Kuhlmann Andersen COO (55)
- Finn Fjorder EVP
- Christopher Bird OTH
- Kirsten Drejer DRC (65)
- Christopher Lindop DRC (62)
- Peter Moerch Eriksen DRC (61)
- Michael Singer DRC
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- November 22nd, 1917
- Public Since
- January 2nd, 1985
- No. of Shareholders
- 19,472
- No. of Employees
- 48
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange - Copenhagen
- Shares in Issue
- 454,657,461
- Address
- Tuborg Havnevej 15, St., HELLERUP, 2900
- Web
- https://bioporto.com/
- Phone
- +45 45290000
- Contact
- Christina Thomsen
- Auditors
- Deloitte Limited
Latest News for BIOPOR
Upcoming Events for BIOPOR
Q2 2025 Bioporto A/S Earnings Release
Q3 2025 Bioporto A/S Earnings Release
Similar to BIOPOR
Ambu A/S
OMX Nordic Exchange - Copenhagen
Bactiquant A/S
OMX Nordic Exchange - Copenhagen
ChemoMetec A/S
OMX Nordic Exchange - Copenhagen
Coloplast A/S
OMX Nordic Exchange - Copenhagen
Demant A/S
OMX Nordic Exchange - Copenhagen
FAQ
As of Today at 19:36 UTC, shares in BioPorto A/S are trading at DKK1.45. This share price information is delayed by 15 minutes.
Shares in BioPorto A/S last closed at DKK1.45 and the price had moved by -32.56% over the past 365 days. In terms of relative price strength the BioPorto A/S share price has underperformed the FTSE Global All Cap Index by -36.33% over the past year.
The overall consensus recommendation for BioPorto A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBioPorto A/S does not currently pay a dividend.
BioPorto A/S does not currently pay a dividend.
BioPorto A/S does not currently pay a dividend.
To buy shares in BioPorto A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of DKK1.45, shares in BioPorto A/S had a market capitalisation of DKK659.25m.
Here are the trading details for BioPorto A/S:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: BIOPOR
Based on an overall assessment of its quality, value and momentum BioPorto A/S is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in BioPorto A/S is DKK4.00. That is 175.86% above the last closing price of DKK1.45.
Analysts covering BioPorto A/S currently have a consensus Earnings Per Share (EPS) forecast of -DKK0.18 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioPorto A/S. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -4.18%.
As of the last closing price of DKK1.45, shares in BioPorto A/S were trading -9.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BioPorto A/S PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at DKK1.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BioPorto A/S' management team is headed by:
- Thomas Magnussen - CHM
- Anthony Pare - CEO
- Torben Nielsen - VCH
- Neil Goldman - CFO
- Jan Kuhlmann Andersen - COO
- Finn Fjorder - EVP
- Christopher Bird - OTH
- Kirsten Drejer - DRC
- Christopher Lindop - DRC
- Peter Moerch Eriksen - DRC
- Michael Singer - DRC